Research Focus
The genetic basis of depression is associated with delicate imbalances in the neurotransmitter systems of individuals. In particular, serotonin transporter polymorphisms in the SLC6A4 gene are key genetic variations that may influence susceptibility to the disease and response to treatment. In addition, variations in inflammatory genes such as IL-6 and TNF-α play a key role in the biological mechanisms of depression. In the treatment process, CYP450 enzyme variants (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4), which are effective in the metabolism of antidepressants such as SSRIs, are the focus of pharmacogenetic studies.
The Depression Working Group, which operates within the Center for Personalized Treatment (KİMER), continues its work with an innovative vision aiming to analyze the genetic and pharmacogenetic basis of depression. This group focuses on the following goals with the aim of developing individualized treatment strategies:
Goals oftheWorking Group:
- Pharmacogenetic Perspective: To examine the impact of genetic factors that determine individual response to medications used in the treatment of depression.
- Genetic Predisposition: To investigate the interaction of genetic and environmental factors involved in the pathogenesis of depression and to create models that can provide risk prediction.
- Clinical Applications: To develop genetic-based personalized treatment panels that can be used in the treatment of depression.
These focus areas have both scientific and clinical potential for the individualized treatment of depression. By integrating genetic data into clinical practice, the working group aims to develop strategies that optimize each individual's response to treatment.